Genetic tests like DecisionDX for squamous cell carcinoma are evolving from simply predicting recurrence risk to actively informing treatment choices. Ongoing studies are exploring whether these tests can determine a patient's potential benefit from adjuvant radiation therapy, representing a critical step toward personalized medicine.

An overall survival (OS) benefit in an adjuvant trial may not be meaningful for patients in systems (e.g., the U.S.) with guaranteed access to the same effective immunotherapy upon recurrence. The crucial, unanswered question is whether treating micrometastatic disease is inherently superior to treating macroscopic disease later, a distinction current trial data doesn't clarify.

Contrary to the common assumption that metastatic disease is the primary cause of cancer-related death, a large international study on CSCC found that two-thirds of patients died from local-regional uncontrolled progression. This highlights the critical importance of effective local control strategies.

In a subset analysis of the high-risk MONARCH-E trial, an inferred Oncotype score did not identify which patients benefited from the CDK4/6 inhibitor abemaciclib. This indicates that while such scores assess prognostic risk and guide chemotherapy decisions, they are not predictive biomarkers for selecting patients for this targeted therapy.

The RSClin tool integrates a patient's Oncotype DX score with their unique clinical-pathologic features, such as tumor size and grade. This provides a more accurate and personalized risk assessment, as the same genomic score can represent significantly different prognoses for patients who have low versus high clinical risk factors.

Experts advise against using gene expression profiling to escalate care for CSCC (e.g., deciding to add systemic therapy). Its primary utility is in de-escalation: a low-risk profile can provide an additional data point to support a decision for observation in a borderline high-risk case, helping to avoid overtreatment.

The Rampart study's use of the Leibovic score for risk stratification is a key strength. Unlike traditional TNM staging, this score more heavily weights tumor grade, which clinicians find to be a more granular and clinically relevant predictor of recurrence risk than just tumor size.

Clinical experience suggests that CSCC recurring within or at the edge of a prior radiation field tends to exhibit more aggressive biological behavior. This context is a critical factor when assessing risk and deciding on subsequent treatment, such as adjuvant systemic therapy, even if other features seem borderline.

Experts warn against over-interpreting a single negative ctDNA test after surgery, clarifying that these patients still face a significant 25-30% risk of recurrence. The biomarker's true prognostic power comes from serial testing that shows a patient remains persistently negative over time.